000130503 001__ 130503
000130503 005__ 20240228143439.0
000130503 0247_ $$2doi$$a10.1016/j.bbi.2015.10.005
000130503 0247_ $$2pmid$$apmid:26456694
000130503 0247_ $$2ISSN$$a0889-1591
000130503 0247_ $$2ISSN$$a1090-2139
000130503 0247_ $$2altmetric$$aaltmetric:4617202
000130503 037__ $$aDKFZ-2017-05582
000130503 041__ $$aeng
000130503 082__ $$a610
000130503 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000130503 245__ $$aCancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients.
000130503 260__ $$aOrlando, Fla. [u.a.]$$bElsevier$$c2016
000130503 3367_ $$2DRIVER$$aarticle
000130503 3367_ $$2DataCite$$aOutput Types/Journal article
000130503 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524811901_6737
000130503 3367_ $$2BibTeX$$aARTICLE
000130503 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130503 3367_ $$00$$2EndNote$$aJournal Article
000130503 520__ $$aFatigue is a major burden for breast cancer patients undergoing adjuvant therapy. Yet, its pathophysiology is still not well understood. Hypothesized mechanisms include dysregulations in the hypothalamic-pituitary-adrenal (HPA) axis, which may be reflected in alterations in the diurnal cortisol patterns. However, studies on the association between cortisol and fatigue during adjuvant cancer therapy are rare. We therefore assessed salivary cortisol at awakening, 0.5h post-awakening, noon, 5 pm and 10 pm/bedtime in 265 breast cancer patients undergoing adjuvant therapy at three timepoints. Cancer-related fatigue was assessed with the Fatigue Assessment Questionnaire (FAQ) covering the physical, affective, and cognitive fatigue dimensions. Multiple linear regression analyses were performed cross-sectionally at the three timepoints as well as longitudinally considering changes in cortisol and fatigue over time. The results showed that the physical dimension of cancer-related fatigue was significantly associated with increased evening cortisol levels and higher overall cortisol secretion. These associations were independent of depressive symptoms. Morning cortisol levels, the cortisol awakening response and the diurnal slope were not consistently associated with physical fatigue. Affective and cognitive fatigue showed no clear association with any of the cortisol parameters. In conclusion, the physical but not the affective or cognitive dimension of fatigue seems associated with cortisol dysregulations in breast cancer patients undergoing adjuvant therapy, characterized by an unaffected cortisol level in the morning but blunted decline to the evening level. Research focusing on disturbances of the cortisol rhythm and HPA dysregulations during and after cancer treatment may open new strategies to reduce cancer-related fatigue.
000130503 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130503 588__ $$aDataset connected to CrossRef, PubMed,
000130503 650_7 $$0WI4X0X7BPJ$$2NLM Chemicals$$aHydrocortisone
000130503 7001_ $$0P:(DE-HGF)0$$aSemik, Johanna$$b1
000130503 7001_ $$0P:(DE-HGF)0$$aHabermann, Nina$$b2
000130503 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b3$$udkfz
000130503 7001_ $$0P:(DE-HGF)0$$aUlrich, Cornelia M$$b4
000130503 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$eLast author$$udkfz
000130503 773__ $$0PERI:(DE-600)1462491-6$$a10.1016/j.bbi.2015.10.005$$gVol. 52, p. 98 - 105$$p98 - 105$$tBrain, behavior and immunity$$v52$$x0889-1591$$y2016
000130503 909CO $$ooai:inrepo02.dkfz.de:130503$$pVDB
000130503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130503 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000130503 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130503 9141_ $$y2016
000130503 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130503 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130503 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130503 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130503 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN BEHAV IMMUN : 2015
000130503 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130503 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130503 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130503 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130503 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130503 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130503 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130503 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130503 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN BEHAV IMMUN : 2015
000130503 9201_ $$0I:(DE-He78)G111-20160331$$kG111$$lBewegung, Sport und Krebs$$x0
000130503 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x1
000130503 980__ $$ajournal
000130503 980__ $$aVDB
000130503 980__ $$aI:(DE-He78)G111-20160331
000130503 980__ $$aI:(DE-He78)G210-20160331
000130503 980__ $$aUNRESTRICTED